BMO Capital Maintains Market Perform on Paycor HCM, Raises Price Target to $33
BMO Capital analyst Daniel Jester maintains Paycor HCM (NASDAQ:PYCR) with a Market Perform and raises the price target from $26 to $33.
DA Davidson Maintains Neutral on Paycor HCM, Raises Price Target to $32
DA Davidson analyst Robert Simmons maintains Paycor HCM (NASDAQ:PYCR) with a Neutral and raises the price target from $28 to $32.
Truist Securities Maintains Buy on Paycor HCM, Raises Price Target to $44
Truist Securities analyst Terry Tillman maintains Paycor HCM (NASDAQ:PYCR) with a Buy and raises the price target from $42 to $44.
Deutsche Bank Maintains Hold on Paycor HCM, Raises Price Target to $36
Deutsche Bank analyst Bhavin Shah maintains Paycor HCM (NASDAQ:PYCR) with a Hold and raises the price target from $30 to $36.
Baird Maintains Outperform on Paycor HCM, Raises Price Target to $39
Baird analyst Mark Marcon maintains Paycor HCM (NASDAQ:PYCR) with a Outperform and raises the price target from $37 to $39.
Earnings Scheduled For August 23, 2022
Companies Reporting Before The Bell
• Regis (NYSE:RGS) is estimated to report earnings for its fourth quarter.
• Jianpu Technology (NYSE:JT) is likely to report earnings for its second quarter.
Why Is This Analyst Optimist Over Absolute Software, Paycor, Zuora Results This Week?
Needham analyst Scott Berg acknowledged that June-quarter earnings would conclude this week while July-quarter earnings fire up with five…
Credit Suisse Maintains Outperform on Paycor HCM, Lowers Price Target to $32
Credit Suisse analyst Kevin Mcveigh maintains Paycor HCM (NASDAQ:PYCR) with a Outperform and lowers the price target from $35 to $32.
Paycor HCM Q3 EPS $0.11 Beats $0.10 Estimate, Sales $122.60M Beat $117.49M Estimate
Paycor HCM (NASDAQ:PYCR) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.10 by 10 percent. The company reported quarterly sales of $122.60 million which beat the analyst
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.